2022
Oral Adverse Events Following COVID-19 Vaccination: Analysis of VAERS Reports
RIAD, Abanoub, Ave POLD, Elham KATEEB a Sameh ATTIAZákladní údaje
Originální název
Oral Adverse Events Following COVID-19 Vaccination: Analysis of VAERS Reports
Autoři
RIAD, Abanoub (818 Egypt, domácí), Ave POLD (203 Česká republika), Elham KATEEB a Sameh ATTIA (garant)
Vydání
Frontiers in Public Health, Lausanne, Frontiers, 2022, 2296-2565
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30304 Public and environmental health
Stát vydavatele
Švýcarsko
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 5.200
Kód RIV
RIV/00216224:14110/22:00126236
Organizační jednotka
Lékařská fakulta
UT WoS
000830988400001
Klíčová slova anglicky
anaphylaxis; COVID-19 vaccines; drug-related side effects and adverse reactions; oral manifestations; pharmacovigilance oral adverse events following COVID-19 vaccination 2
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 5. 4. 2023 08:16, Mgr. Tereza Miškechová
Anotace
V originále
Background: Oral adverse events (AEs) following COVID-19 vaccination have been sporadically reported during the previous months, warranting further investigation for their prevalence and suspected relationship with vaccine-elicited immune response. Methods: A retrospective analysis using the Vaccine Adverse Event Reporting System (VAERS) data was conducted to evaluate AEs within the oral cavity (mucosa, tongue, lips, palate, dentition, salivary glands) and AEs involving taste and other sensations. Oral AEs reported after receiving COVID-19 vaccination (test group) and seasonal influenza vaccination (control group) were extracted and cross-tabulated to assess their relative prevalence. Results: Among the 128 solicited (suspected) oral AEs, oral paresthesia (0.872%) was most reported after receiving COVID-19 vaccines, followed by the swelling of lips (0.844%), ageusia (0.722%), oral hypoesthesia (0.648%), swollen tongue (0.628%), and dysgeusia (0.617%). The reported prevalence of oral AEs was higher in the COVID-19 vaccine group than in the seasonal influenza group. The distribution pattern of the most reported oral AEs was similar for both COVID-19 and seasonal influenza vaccines. Female sex, older age (>39 years old), primer doses, and mRNA-based COVID-19 vaccines exhibited a higher reported prevalence of oral AEs. Conclusion: Within the limitations of this study, COVID-19 vaccines were found to be associated with rare oral AEs that are predominantly similar to those emerging following seasonal influenza vaccines. The most commonly reported oral AEs were oral paraesthesia (mouth-tingling), lip swelling, and ageusia, representing various pathophysiologic pathways that remain unclear. Taste-related AEs should be acknowledged in the context of the COVID-19 pandemic and the public should be adequately informed about a potential taste dysfunction after receiving the COVID-19 vaccination. Dentists and dental teams need to be aware of the prevalence, severity, and prognosis of oral AEs to inform their patients and increase public confidence in vaccines.
Návaznosti
EF19_073/0016943, projekt VaV |
| ||
MUNI/A/1402/2021, interní kód MU |
| ||
MUNI/IGA/1104/2021, interní kód MU |
|